Wegovy's original use and how it became a licensed weight-loss medicine

Step 1: semaglutide starts life as a diabetes drug

The GLP-1 receptor agonist class was built, originally, around blood-sugar control. Researchers noticed that a gut hormone called GLP-1 (released after eating) stimulates insulin secretion and suppresses glucagon. Mimicking it pharmacologically looked like a promising route for type 2 diabetes management. Novo Nordisk developed semaglutide on that basis, and it reached the market as Ozempic (and separately as the oral tablet Rybelsus) for type 2 diabetes.

What the diabetes trials revealed fairly quickly was that patients taking semaglutide were also losing meaningful amounts of weight, more than could be explained by the blood-sugar effect alone. Appetite was falling. Food felt less urgent. That observation opened a separate research question: if a higher dose were titrated specifically for weight management, what would happen in people living with obesity but without diabetes?

The origin of semaglutide as a compound is worth understanding here, because it shapes how regulators and prescribers think about it. The mechanism was not invented for weight loss. It was adapted for it, carefully, and with a substantial clinical programme behind it. You can read more about the compound's wider history on our semaglutide overview.

Step 2: the STEP programme builds the weight-management evidence base

Novo Nordisk ran a series of dedicated trials (the STEP programme) testing semaglutide 2.4 mg weekly in adults with obesity or overweight alongside weight-related conditions, but without type 2 diabetes. STEP 1, the flagship trial, enrolled 1,961 adults and ran for 68 weeks. The results, published in the New England Journal of Medicine, showed an average body-weight reduction of around 15% in the semaglutide group, compared with around 2.4% in participants taking a placebo.

Those figures gave regulators enough to work with. The MHRA licensed Wegovy in the UK for weight management, distinct from Ozempic's diabetes licence. Same molecule, different dose, different indication, different product name. Ozempic remains a diabetes medicine; it is not licensed for weight loss and prescribers cannot lawfully prescribe it for that purpose. The Wegovy overview on this site sets out the current UK licence in full.

One practical check you can do in under a minute: search the eMC (electronic Medicines Compendium) for 'Wegovy' and 'Ozempic' side by side. The licensed indications are listed at section 4.1 of each Summary of Product Characteristics. They are not the same document.

Step 3: understanding what the licensed weight-management indication actually covers

The UK licence for Wegovy applies to adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, or cardiovascular disease. Treatment is intended to run alongside a reduced-calorie diet and increased physical activity, not instead of them.

NICE has issued its own recommendation for semaglutide (TA875), specifying that NHS use should sit within a specialist weight management service and run for a maximum of two years. Private prescribing follows the licensed criteria rather than the NHS commissioning criteria, though the clinical assessment remains the same in substance. A prescriber considers the full picture: medical history, current medicines, any contraindications, and whether Wegovy or tirzepatide (Mounjaro) is the better fit for the individual patient. The practical guide to using Wegovy covers what happens once treatment starts. For a broader look at all available options, the weight-loss treatment overview is a useful starting point.

Cost is a real consideration for many people exploring private treatment. Our guide to where Wegovy can be obtained in the UK covers what to check before committing to any provider. For context on what private pricing typically involves, the treatment page sets out everything included in a nume consultation.

Step 4: semaglutide's authorisations keep expanding

Since Wegovy's weight-management licence was granted, semaglutide has continued to accumulate new authorisations. It now holds a UK indication for reducing the risk of major cardiovascular events in eligible adults with established cardiovascular disease and obesity. More recently, in July 2026, the MHRA granted conditional approval for semaglutide (Wegovy) to treat MASH, a form of fatty liver disease involving moderate-to-advanced fibrosis. Neither of these indications is the same as the weight-loss licence, and a prescriber assesses which, if any, applies to a given patient.

There is also, as of June 2026, a licensed oral form: Wegovy tablets, approved by the MHRA as the first oral GLP-1 medicine for weight management in the UK. The active ingredient is still semaglutide, co-formulated with an absorption enhancer to allow once-daily dosing by mouth. The tablet represents a further step away from Wegovy's original use as an injected diabetes medicine, the same science, applied to a different delivery route and a different patient need.

The story behind the Wegovy name and the country where Wegovy was first approved add useful context for anyone tracing how this medicine moved from diabetes research into mainstream weight management. Our dedicated page on what Wegovy was originally used for goes into greater depth on the regulatory history. The NHS patient information on semaglutide, available at nhs.uk/medicines/semaglutide, is the plain-language reference for what to expect from treatment.

If any of this has made you curious about whether Wegovy or another licensed treatment might suit you, our prescribers review consultations the same day they are submitted. Check your eligibility by starting a free consultation, no waiting list, clinical assessment included.